Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $1,072,164.30 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 7,143 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.10, for a total transaction of $1,072,164.30. Following the completion of the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $376,300.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, August 6th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10.

Neurocrine Biosciences Stock Up 0.7 %

Shares of Neurocrine Biosciences stock traded up $1.08 during trading hours on Thursday, hitting $147.77. The company’s stock had a trading volume of 720,170 shares, compared to its average volume of 819,548. Neurocrine Biosciences, Inc. has a 1-year low of $103.63 and a 1-year high of $157.98. The business has a fifty day moving average of $141.47 and a 200 day moving average of $138.88. The company has a market capitalization of $14.87 billion, a PE ratio of 40.55 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. During the same period in the previous year, the company earned $0.95 EPS. Neurocrine Biosciences’s revenue was up 30.4% on a year-over-year basis. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its holdings in Neurocrine Biosciences by 10.5% during the 4th quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock valued at $103,000 after purchasing an additional 74 shares in the last quarter. Quadrant Capital Group LLC grew its holdings in Neurocrine Biosciences by 3.9% during the 4th quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock valued at $273,000 after purchasing an additional 78 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in Neurocrine Biosciences by 3.2% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock valued at $333,000 after purchasing an additional 78 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Neurocrine Biosciences by 0.6% during the 1st quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after purchasing an additional 84 shares in the last quarter. Finally, Balentine LLC grew its holdings in Neurocrine Biosciences by 4.0% during the 4th quarter. Balentine LLC now owns 2,316 shares of the company’s stock valued at $305,000 after purchasing an additional 89 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on NBIX. Barclays upped their price target on shares of Neurocrine Biosciences from $169.00 to $180.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. HC Wainwright upped their price target on shares of Neurocrine Biosciences from $160.00 to $190.00 and gave the company a “buy” rating in a report on Monday, August 5th. Morgan Stanley upped their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Thursday, August 1st. Finally, Robert W. Baird upped their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $158.68.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.